Evidence map›Paper›PMID 28924126›Full record

ArticleInternal medicine (Tokyo, Japan)2017

Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment.

Hiroaki Tanaka, Hanako Aoki, Yasumasa Sugita, Ryo Shimizu, Katsunari Kiko, Hidetoshi Mochida, Yoshio Suzuki

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.International journal of molecular sciences · 2024
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hiroaki TanakaDepartment of Hematology, Asahi General Hospital, Japan.
Hanako AokiDepartment of Internal Medicine, Asahi General Hospital, Japan.
Yasumasa SugitaDepartment of Hematology, Asahi General Hospital, Japan.
Ryo ShimizuDepartment of Hematology, Asahi General Hospital, Japan.
Katsunari KikoDepartment of Neurosurgery, Asahi General Hospital, Japan.
Hidetoshi MochidaDepartment of Neurosurgery, Asahi General Hospital, Japan.
Yoshio SuzukiDepartment of Diagnostic Pathology, Asahi General Hospital, Japan.
Asahi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor type 4 (CCR4) antibody that exerts an anti-tumor immune effect against various tumors through a suppressive effect on regulatory T-cells. We herein report a patient with peripheral T-cell lymphoma who developed Epstein-Barr virus (EBV)-related primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) after mogamulizumab therapy. Our experience should alert physicians to the possibility of the development of EBV-related CNS DLBCL in patients treated for primary lymphoma and suggests that the anti-tumor immune effect of mogamulizumab is ineffective for the prophylaxis of EBV-related lymphomas.

Indexed as

Herpesvirus 4, HumanAgedAntibodies, Monoclonal, HumanizedCentral Nervous System DiseasesFemaleHumansLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell, PeripheralMaleReceptors, CCR4T-Lymphocytes, RegulatoryAntibodies, Monoclonal, HumanizedmogamulizumabReceptors, CCR4CNS DLBCLEBVmogamulizumabPTCL-NOSsecondary malignancy

Identifiers

PMID28924126
PMCPMC5675939
OpenAlexW2755440622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.